NAVB has been in an uptrend since 5/9/13. It has been under accumulation in a steady trading range. Recent news confirming the superiority of Lymphoseek for lymphatic mapping and the detection of cancerous lymph nodes for surgical staging has possibly created the conditions for a breakout. The Jan 14 $3 calls are cheap and if estimates of $5 pps are reached by eoy will be trading at many multiples of their current bid. A simple move to $3.20 any time soon and they should more than double.

http://lifetechcapital.com/ltc/wp-content/upl...3-NAVB.pdf